Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04763356 · ClinicalTrials.gov registry record · NA

Remote Monitoring and Management of Chemotherapy Induced Peripheral Neuropathy

A NA study of Chemotherapy-induced Peripheral Neuropathy, sponsored by University of Vermont.

Recruiting
Registry status
NA
Development phase
422
Enrollment target
3
Study locations

NCT04763356 is a NA study of Chemotherapy-induced Peripheral Neuropathy that is actively recruiting participants, run by University of Vermont. The registered enrollment target is 422 participants, above the 124-participant average among 29 other Chemotherapy-induced Peripheral Neuropathy trials with a reported enrollment target (240% higher). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04763356, a NA study of Chemotherapy-induced Peripheral Neuropathy, is actively recruiting participants, sponsored by University of Vermont.

RECRUITING
Registry status
NA
Development phase
422 participants
Enrollment target
3
Study locations

Study Summary

This is a prospective randomized trial designed to investigate a new care model for patients who suffer from nerve damage from chemotherapy called chemotherapy induced peripheral neuropathy (CIPN). All participants in the study will report their CIPN symptoms daily using a website, app or phone for 12 weeks. In one group the data will be collected and participants will be encouraged to reach out to their treating doctors for uncontrolled symptoms. These participants' doctors can prescribe any treatment they feel is appropriate. In the second group, if the symptoms meet the criteria for eligibility they will receive a phone call from a nurse practitioner either the same day or next day, depending on the time symptoms were logged. That nurse practitioner will determine the correct CIPN treatment using an algorithm and prescribe it. The study will track the severity of symptoms over time as well as looking at the impact on treatments for CIPN (medications and referrals).

Interventions

  • OTHER Symptom Care at Home with NP follow up

Study Locations (3)

Utah

  • University of Utah - Salt Lake City

Vermont

  • University of Vermont - Burlington

Virginia

  • Virginia Commonwealth University Massey Cancer Center - Richmond

Trial Details

FieldValue
Enrollment Target 422 participants
Start Date 2023-01-10
Est. Completion 2026-09-30
Phase NA

Sponsor

University of Vermont

162 total trials

What the Registry Record Tells You About NCT04763356

The ClinicalTrials.gov registry entry for NCT04763356 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 422 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 124-participant average among 29 other Chemotherapy-induced Peripheral Neuropathy trials with a reported enrollment target (240% higher). The listed sponsor is University of Vermont, which has 162 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chemotherapy-induced Peripheral Neuropathy appearing as the primary indexed condition, and to 1 intervention - of which Symptom Care at Home with NP follow up is the first listed.

NCT04763356 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Utah, Vermont, Virginia.

Frequently Asked Questions

What is clinical trial NCT04763356 about?

NCT04763356 is a clinical study titled "Remote Monitoring and Management of Chemotherapy Induced Peripheral Neuropathy". This is a prospective randomized trial designed to investigate a new care model for patients who suffer from nerve damage from chemotherapy called chemotherapy induced peripheral neuropathy (CIPN). All participants in the study will report their CIPN symptoms daily using a website, app or phone for ...

What is the current status of trial NCT04763356?

This trial is currently recruiting. It is a NA study. The enrollment target is 422 participants. The study started on 2023-01-10. Estimated completion is 2026-09-30.

What conditions does trial NCT04763356 study?

This clinical trial studies the following conditions: Chemotherapy-induced Peripheral Neuropathy.

What interventions are being tested in trial NCT04763356?

The interventions under investigation include: Symptom Care at Home with NP follow up (OTHER).

Who is sponsoring clinical trial NCT04763356?

This trial is sponsored by University of Vermont, which has 162 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04763356 being conducted?

This trial has 3 study locations across Utah, Vermont, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chemotherapy-induced Peripheral Neuropathy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.